普洛药业: 半年报董事会决议公告

Core Points - The company held its 14th meeting of the 9th Board of Directors on August 18, 2025, with all 7 directors present, and approved several key resolutions [1][2][5] - The company approved the full and summary report for the first half of 2025, with unanimous support from the board [1][5] - The board decided to adjust its composition, increasing the number of directors from 7 to 9, adding one non-independent director and one employee representative director [1][2] Governance Structure Adjustments - The Strategic Committee was renamed to the Strategic and ESG Committee, reducing its members from 7 to 5, with the chairman serving as the head [2] - The Audit Committee's membership was reduced from 5 to 3, with two independent directors, one of whom is an accounting professional, serving as the head [2] - The Nomination Committee and the Compensation and Assessment Committee were both reduced to 3 members, with two independent directors in each [2][3] Institutional Revisions - The company approved multiple revisions to its internal regulations, including the Articles of Association, rules for shareholder meetings, and board meeting rules, all requiring shareholder approval [2][3][4] - The company also revised various management systems, including those for fundraising, external investments, and guarantees, with unanimous board support [3][4][5] New Director Nomination - The board nominated Mr. Li Baoping as a candidate for a non-independent director position, pending approval at the upcoming shareholder meeting [4][5] - Mr. Li has extensive experience in management and currently holds several positions within the controlling shareholder's companies [7] Profit Distribution and Shareholder Meeting - The board approved the mid-year profit distribution plan for 2025, which will also be submitted for shareholder approval [5] - A proposal for convening the first temporary shareholder meeting of 2025 was also approved [5]